SPYRE THERAPEUTICS, INC. Income (Loss) from Equity Method Investments
SPYRE THERAPEUTICS, INC. (SYRE) reported Income (Loss) from Equity Method Investments of -$83.95 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-02.
Discontinued › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2023-03-02
- SPYRE THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2022 was -$83.95M.
- SPYRE THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2021 was -$65.66M.
- SPYRE THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2020 was -$80.89M.
- SPYRE THERAPEUTICS, INC. income (loss) from equity method investments for fiscal 2019 was -$78.25M.
| Period end | Income (Loss) from Equity Method Investments 12 month |
|---|---|
| 2022-12-31 | -$83.95M 10-K · filed 2023-03-02 |
| 2021-12-31 | -$65.66M 10-K · filed 2023-03-02 |
| 2020-12-31 | -$80.89M 10-K · filed 2023-03-02 |
| 2019-12-31 | -$78.25M 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |